Positron emission tomography/computed tomography (PET/CT) is a hybrid imaging modality that has recently experienced a wide increase in its use and applications. The most common tracer used to perform such a diagnostic procedure is 18F-fluorodeoxyglucose ([18F]FDG), which has the ability to reveal hypermetabolic lesions based on their increased glycolytic metabolism. As a consequence, [18F]FDG PET/CT has proven its role to assess neoplastic disease both in staging and restaging settings [1,2,3,4,5]. However, its usefulness for the evaluation of inflammatory and infectious diseases has also emerged, in particular in the last decade [6,7,8,9].
In order to evaluate metabolic pathways different from the glucose metabolism, several positron emitters tracers have been proposed as an alternative to [18F]FDG. In this setting, fibroblast activation protein (FAP) inhibitors (FAPI), labelled with both 18F or 68Ga, are emerging as promising radiopharmaceuticals. FAPI are molecules able to bind to FAP, a membrane serine protease that is highly expressed on activated fibroblasts present in a wide range of pathophysiological conditions, such as wound-healing, inflammation and cancer [10,11,12]. In this scenario, the role of FAPI PET/CT for the evaluation of cancer has been evaluated in several studies and the preliminary results are promising, as it also seems to allow the evaluation of tumors with low [18F]FDG uptake. Interestingly, when coupled together, [18F]FDG and radiolabeled FAPI are able to better define and comprehend tumoral metabolic heterogeneity [10,13,14,15,16].
The role of FAPI imaging is, however, also emerging for the assessment of inflammatory and infectious diseases, even if the evidence in the literature is still in its early stages [10,17,18]. It has been reported that focal radiolabeled FAPI uptake is related to active tissue remodeling in patients with immune-mediated inflammatory diseases that are characterized by the presence of chronic inflammation and tissue response. As a consequence, benign lesions are frequently characterized by the presence of FAPI uptake, and bones or joints are frequently the sites of such findings [18]. Interestingly, inflammatory lesions are not always positive to [18F]FDG PET, indicating that inflammation and the related tissue response could be disentangled by the combination of both tracers [19].
The rationale behind the use of FAPI PET/CT for the assessment of inflammatory bone and joint diseases is that FAP is overexpressed in tissue remodeling sites associated with arthritis and fibrosis, such as chondrocytes [10,11]. However, on the other side, some authors hypothesized a different mechanism of uptake, related to the increased vascularity and capillary permeability due to inflammatory response, resulting in high perfusion and blood-pool effects [20]. Nevertheless, one of the advantages of the use of FAPI imaging for the assessment of bone lesions is the fact that bone marrow usually exhibits low physiological FAPI uptake [12,18].
In this scenario, a recent article compared the radiolabeled FAPI uptake in bones and joints between malign and benign lesions (such as periodontitis, osteofibrous dysplasia, degenerative bone disease, arthritis and trauma related lesions) [21]. The authors reported that, even if overlap occurred in some cases, maximum standardized uptake value (SUVmax) of bone metastases was significantly higher compared to benign lesions, even if no significant differences in terms of uptake between such benign lesions was reported, with the exception of periodontitis. Furthermore, in general, the SUVmax of radiolabeled FAPI PET was higher compared to SUVmax of [18F]FDG PET, with the exception of degenerative disease. The authors also underlined that the features of FAPI-positive benign lesions were the presence of solitary lesions, lower uptake and specific locations, such as the joints.
Several case reports have reported that radiolabeled FAPI uptake is associated with a high number of benign conditions that affect the bones and the joints, such as fibrous dysplasia [22], tuberculosis [23], osteoarthritis, enthesopathies, myositis ossificans [24], Erdheim–Chester disease [25], ankylosing spondylitis [26], fractures [20], synovitis, osteitis and rheumatoid arthritis (RA) [12]. In particular, arthritis is generally underlined as an incidental finding at radiolabeled FAPI PET/CT and the most common sites of uptake are facet, shoulder, sternoclavicular joints and knees [11,20,27,28,29].
Some articles focused particularly on the role of FAPI imaging for the assessment of RA in preclinical setting, with the demonstration of the high specificity of this tracer for arthritic joints, both in vitro and in vivo. In this setting, some pilot clinical evaluations for the use of radiolabeled FAPI PET/CT in subjects with RA have also been proposed, suggesting its potential application to visualize arthritic synovium related to the specific upregulation of the expression of FAP in this site [10,30,31].
The ability of [18F]FDG and FAPI imaging to evaluate periprosthetic joint infection (PJI) and aseptic loosening were also compared in preclinical setting, revealing that radiolabeled FAPI PET had higher sensitivity and specificity and had the potential to define more accurately such lesions. Furthermore, FAPI PET had greater potential in the diagnosis of PJI and distinct advantages compared to [18F]FDG [32].
To conclude, the role of radiolabeled FAPI PET/CT for the assessment of benign inflammatory and infectious diseases of bone and joints is still in an embryonal phase; however, some insights on its usefulness are emerging. Further data, in particular in clinical settings, are however needed to confirm and better define the advantages of FAPI imaging for the evaluation of such benign lesions, in particular in comparison to [18F]FDG.
Institutional Review Board Statement
Not applicable.
Informed Consent Statement
Not applicable.
Conflicts of Interest
The authors declare no conflict of interest.
Funding Statement
This research received no external funding.
Footnotes
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Parpinel G., Laudani M.E., Giunta F.P., Germano C., Zola P., Masturzo B. Use of Positron Emission Tomography for Pregnancy-Associated Cancer Assessment: A Review. J. Clin. Med. 2022;11:3820. doi: 10.3390/jcm11133820. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Albano D., Pasinetti N., Dondi F., Giubbini R., Tucci A., Bertagna F. Prognostic Role of Pre-Treatment Metabolic Parameters and Sarcopenia Derived by 2-[18F]-FDG PET/CT in Elderly Mantle Cell Lymphoma. J. Clin. Med. 2022;11:1210. doi: 10.3390/jcm11051210. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Dondi F., Pasinetti N., Gatta R., Albano D., Giubbini R., Bertagna F. Comparison between Two Different Scanners for the Evaluation of the Role of 18F-FDG PET/CT Semiquantitative Parameters and Radiomics Features in the Prediction of Final Diagnosis of Thyroid Incidentalomas. J. Clin. Med. 2022;11:615. doi: 10.3390/jcm11030615. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Albano D., Gatta R., Marini M., Rodella C., Camoni L., Dondi F., Giubbini R., Bertagna F. Role of 18F-FDG PET/CT Radiomics Features in the Differential Diagnosis of Solitary Pulmonary Nodules: Diagnostic Accuracy and Comparison between Two Different PET/CT Scanners. J. Clin. Med. 2021;10:5064. doi: 10.3390/jcm10215064. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Lopci E. Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [18F]FDG PET/CT in Metastatic Melanomas and Lung Cancer. J. Clin. Med. 2021;10:5160. doi: 10.3390/jcm10215160. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Reinert C.P., Pfannenberg C., Dittmann H., Gückel B., la Fougère C., Nikolaou K., Hoefert S. [18F]Fluoride Positron-Emission Tomography (PET) and [18F]FDG PET for Assessment of Osteomyelitis of the Jaw in Comparison to Computed Tomography (CT) and Magnetic Resonance Imaging (MRI): A Prospective PET/CT and PET/MRI Pilot Study. J. Clin. Med. 2022;11:3998. doi: 10.3390/jcm11143998. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Béra S., Jamilloux Y., Gerfaud-Valentin M., Durupt S., Nove-Josserand R., Lega J.-C., Durieu I., Hot A., Sève P. Inflammation of Unknown Origin: Evaluation and Prognosis of 57 Cases. J. Clin. Med. 2022;11:32. doi: 10.3390/jcm11010032. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Choi J.Y., Jhun B.W., Hyun S.H., Chung M.J., Koh W.-J. 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Assessing Treatment Response of Pulmonary Multidrug-Resistant Tuberculosis. J. Clin. Med. 2018;7:559. doi: 10.3390/jcm7120559. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Ly K.-H., Costedoat-Chalumeau N., Liozon E., Dumonteil S., Ducroix J.-P., Sailler L., Lidove O., Bienvenu B., Decaux O., Hatron P.-Y., et al. Diagnostic Value of 18F-FDG PET/CT vs. Chest-Abdomen-Pelvis CT Scan in Management of Patients with Fever of Unknown Origin, Inflammation of Unknown Origin or Episodic Fever of Unknown Origin: A Comparative Multicentre Prospective Study. J. Clin. Med. 2022;11:386. doi: 10.3390/jcm11020386. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Dendl K., Koerber S.A., Kratochwil C., Cardinale J., Finck R., Dabir M., Novruzov E., Watabe T., Kramer V., Choyke P.L., et al. FAP and FAPI-PET/CT in Malignant and Non-Malignant Diseases: A Perfect Symbiosis? Cancers. 2021;13:4946. doi: 10.3390/cancers13194946. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Erol Fenercioğlu Ö., Beyhan E., Ergül N., Arslan E., Çermik T.F. 18F-FDG PET/CT and 68Ga-FAPI-4 PET/CT Findings of Bilateral Knee Osteoarthritis in a Patient with Uveal Malignant Melanoma. Clin. Nucl. Med. 2022;47:e144–e146. doi: 10.1097/RLU.0000000000003854. [DOI] [PubMed] [Google Scholar]
- 12.Hotta M., Rieger A.C., Jafarvand M.G., Menon N., Farolfi A., Benz M.R., Calais J. Non-oncologic incidental uptake on FAPI PET/CT imaging. Br. J. Radiol. 2022;13:20220463. doi: 10.1259/bjr.20220463. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Gilardi L., Airò Farulla L.S., Demirci E., Clerici I., Omodeo Salè E., Ceci F. Imaging Cancer-Associated Fibroblasts (CAFs) with FAPi PET. Biomedicines. 2022;10:523. doi: 10.3390/biomedicines10030523. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Sollini M., Kirienko M., Gelardi F., Fiz F., Gozzi N., Chiti A. State-of-the-art of FAPI-PET imaging: A systematic review and meta-analysis. Eur. J. Nucl. Med. Mol. Imaging. 2021;48:4396–4414. doi: 10.1007/s00259-021-05475-0. [DOI] [PubMed] [Google Scholar]
- 15.Roustaei H., Kiamanesh Z., Askari E., Sadeghi R., Aryana K., Treglia G. Could Fibroblast Activation Protein (FAP)-Specific Radioligands Be Considered as Pan-Tumor Agents? Contrast Media Mol. Imaging. 2022;2022:3948873. doi: 10.1155/2022/3948873. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Treglia G., Muoio B., Roustaei H., Kiamanesh Z., Aryana K., Sadeghi R. Head-to-Head Comparison of Fibroblast Activation Protein Inhibitors (FAPI) Radiotracers versus [18F]F-FDG in Oncology: A Systematic Review. Int. J. Mol. Sci. 2021;22:11192. doi: 10.3390/ijms222011192. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Sharma P., Singh S.S., Gayana S. Fibroblast Activation Protein Inhibitor PET/CT: A Promising Molecular Imaging Tool. Clin. Nucl. Med. 2021;46:e141–e150. doi: 10.1097/RLU.0000000000003489. [DOI] [PubMed] [Google Scholar]
- 18.Zheng S., Lin R., Chen S., Zheng J., Lin Z., Zhang Y., Xue Q., Chen Y., Zhang J., Lin K., et al. Characterization of the benign lesions with increased 68Ga-FAPI-04 uptake in PET/CT. Ann. Nucl. Med. 2021;35:1312–1320. doi: 10.1007/s12149-021-01673-w. [DOI] [PubMed] [Google Scholar]
- 19.Kuwert T., Schmidkonz C., Prante O., Schett G., Ramming A. FAPI-PET Opens a New Window for Understanding of Immune-Mediated Inflammatory Diseases. J. Nucl. Med. 2022;63:1136–1137. doi: 10.2967/jnumed.122.263922. [DOI] [PubMed] [Google Scholar]
- 20.Kou Y., Jiang X., Yao Y., Shen J., Jiang X., Chen S., Lu H., Wang X., Zhao M., Xiao D., et al. Physiological tracer distribution and benign lesion incidental uptake of Al18F-NOTA-FAPI-04 on PET/CT imaging. Nucl. Med. Commun. 2022;43:847–854. doi: 10.1097/MNM.0000000000001563. [DOI] [PubMed] [Google Scholar]
- 21.Qin C., Song Y., Liu X., Gai Y., Liu Q., Ruan W., Liu F., Hu F., Lan X. Increased uptake of 68Ga-DOTA-FAPI-04 in bones and joints: Metastases and beyond. Eur. J. Nucl. Med. Mol. Imaging. 2022;49:709–720. doi: 10.1007/s00259-021-05472-3. [DOI] [PubMed] [Google Scholar]
- 22.Song Y., Qin C., Liu F., Lan X. Fibrous Dysplasia Mimicking Skeletal Metastasis on 68Ga-FAPI PET Imaging. Clin. Nucl. Med. 2021;46:774–775. doi: 10.1097/RLU.0000000000003671. [DOI] [PubMed] [Google Scholar]
- 23.Gong W., Yang X., Mou C., Liu H., Zhang C. Bone Tuberculous Granulomatous Inflammation Mimicking Malignancy on 68Ga-FAPI PET/CT. Clin. Nucl. Med. 2022;47:348–349. doi: 10.1097/RLU.0000000000003990. [DOI] [PubMed] [Google Scholar]
- 24.Gong W., Chen S., He L., Liu W., Zhang C. Intense 68Ga-FAPI Uptake in a Patient with Myositis Ossificans: Mimicking Bone Malignancy. Clin. Nucl. Med. 2022;47:638–639. doi: 10.1097/RLU.0000000000004213. [DOI] [PubMed] [Google Scholar]
- 25.Wu S., Pang Y., Chen Y., Sun H., Chen H. 68Ga-DOTA-FAPI-04 PET/CT in Erdheim-Chester Disease. Clin. Nucl. Med. 2021;46:258–260. doi: 10.1097/RLU.0000000000003491. [DOI] [PubMed] [Google Scholar]
- 26.Yao L., Zhao L., Pang Y., Shang Q., Chen H. Increased 68Ga-FAPI Uptake in Ankylosing Spondylitis in a Patient with Rectal Cancer. Clin. Nucl. Med. 2022;47:176–178. doi: 10.1097/RLU.0000000000003798. [DOI] [PubMed] [Google Scholar]
- 27.Luo Y., Pan Q., Yang H., Li F., Zhang F. Inflammatory Arthritis Induced by Anti-Programmed Death-1 Shown in 68Ga-FAPI PET/CT in a Patient with Esophageal Carcinoma. Clin. Nucl. Med. 2021;46:431–432. doi: 10.1097/RLU.0000000000003608. [DOI] [PubMed] [Google Scholar]
- 28.Yang X., You Z., Gong W., Chen Y., Liu H. Increased 68Ga-FAPI Uptake in Facet Joint Osteoarthritis in a Patient with Esophageal Cancer. Clin. Nucl. Med. 2022;47:342–343. doi: 10.1097/RLU.0000000000003957. [DOI] [PubMed] [Google Scholar]
- 29.Xu T., Zhao Y., Ding H., Cai L., Zhou Z., Song Z., Chen Y. [68Ga]Ga-DOTA-FAPI-04 PET/CT imaging in a case of prostate cancer with shoulder arthritis. Eur. J. Nucl. Med. Mol. Imaging. 2021;48:1254–1255. doi: 10.1007/s00259-020-05028-x. [DOI] [PubMed] [Google Scholar]
- 30.Ge L., Fu Z., Wei Y., Shi D., Geng Y., Fan H., Zhang R., Zhang Y., Li S., Wang S., et al. Preclinical evaluation and pilot clinical study of [18F]AlF-NOTA-FAPI-04 for PET imaging of rheumatoid arthritis. Eur. J. Nucl. Med. Mol. Imaging. 2022 doi: 10.1007/s00259-022-05836-3. [DOI] [PubMed] [Google Scholar]
- 31.Dorst D.N., Rijpkema M., Buitinga M., Walgreen B., Helsen M.M.A., Brennan E., Klein C., Laverman P., Ramming A., Schmidkonz C., et al. Targeting of fibroblast activation protein in rheumatoid arthritis patients: Imaging and ex vivo photodynamic therapy. Rheumatology. 2022;61:2999–3009. doi: 10.1093/rheumatology/keab664. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Wang Y., Li Y., Han L., Wang J., Zhang C., Qi E., Zhang D., Zhang X., Huan Y., Tian J. 18F-FDG and 68 Ga-FAPI PET/CT for the evaluation of periprosthetic joint infection and aseptic loosening in rabbit models. BMC Musculoskelet. Disord. 2022;23:592. doi: 10.1186/s12891-022-05537-w. [DOI] [PMC free article] [PubMed] [Google Scholar]